The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously. “As of March 31, 2021, LinkDoc had $125.8 million in cash and $116.5 million in total liabilities,” it said, but added “Free cash flow during the 12 months ended March 31, 2021, was negative ($37.9 million).Necessary cookies are absolutely essential for the website to function properly. #Didi keep ximalaya linkdoc us trial#The company’s primary offerings include: LinkCare (a continuous care platform), LinkData (a longitudinal medical data system) and LinkSolutions (a clinical trial matching service). “LinkDoc has received at least $366 million in equity investment from investors including Digital Medical Technology, New Enterprise Associates, China Broadband Capital, Esta Investments Pte, Lifetech Company and Alibaba Health Technology Company.” “Management is headed by founder and Chief Executive Officer Tianze Zhang, who was previously an employee at Tencent and Alibaba and founded Truststone, which provides health information systems to pharmaceutical and medical institutions. The markets website Seeking Alpha said six days ago: “LDOC is growing quickly, has potentially large expansion capabilities into other health areas and the IPO appears reasonably valued, so is worth consideration. We are developing LinkDoc solutions from these precious real world big data to empower clinical doctors, healthcare industry and patients with better oncology care.” “We have collaborated with 600 departments from 300 top oncology centres in China. “We have developed proprietary machine learning and human language processing enabled mechanism to structure millions of clinical EMR into research grade data,” the group says in its page on LinkedIn. “Through clinical data fusion system, the company helps hospitals and departments to establish a structured electronic medical record database,” it says. listing in favor of Hong Kong earlier this year. Chinese regulators are said to have pressured Ximalaya to drop its U.S. LinkDoc describes itself as a “leading” big data company from China focused on oncology, the treatment of cancer and tumors.īased in Beijing, LDoc, as it is known, has systems that use artificial intelligence to assist in patient management, and other services. LinkDoc Technology, a health care technology firm, and Ximalaya, a platform for audio sharing, have also reportedly delayed their U.S. Analysts says they also suspect that Beijing is pressing domestic companies to list in Hong Kong instead of overseas. The company, which is reportedly backed by Alibaba, filed for an IPO last month and was due to set a price for its shares later today (Thursday July 8).Ĭhinese regulators are concerned about the security of large volumes of personal data accumulated by internet-based platforms that list in the US. LinkDoc Technology Ltd has suddenly shelved an IPO that was set to raise up to $211 million in the US, according to sources who spoke to Reuters and Nikkei. (AF) Chinese medical data group LinkDoc has cancelled an initial public offering in the United States after Beijing ramped up its tech crackdown last week against Didi Global and other companies that listed abroad recently. Medical data group abandons plan for US IPO at the last minute after tech crackdown by Chinese regulators on Didi and other internet-based platforms
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |